Raymond T Chung

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1238823/publications.pdf

Version: 2024-02-01

396	25,749	6254 80	9345 143
papers	citations	h-index	g-index

405	405	405	27798
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A Role for Hepatitis C Virus Infection in Type II Cryoglobulinemia. New England Journal of Medicine, 1992, 327, 1490-1495.	27.0	1,282
2	Analysis of Successful Immune Responses in Persons Infected with Hepatitis C Virus. Journal of Experimental Medicine, 2000, 191, 1499-1512.	8.5	1,165
3	Peginterferon Alfa-2a plus Ribavirin versus Interferon Alfa-2a plus Ribavirin for Chronic Hepatitis C in HIV-Coinfected Persons. New England Journal of Medicine, 2004, 351, 451-459.	27.0	856
4	Drug-Resistant E. coli Bacteremia Transmitted by Fecal Microbiota Transplant. New England Journal of Medicine, 2019, 381, 2043-2050.	27.0	767
5	The epigenetic landscape of T cell exhaustion. Science, 2016, 354, 1165-1169.	12.6	694
6	Hepatitis C Virus Prevalence among Patients Infected with Human Immunodeficiency Virus: A Cross-Sectional Analysis of the US Adult AIDS Clinical Trials Group. Clinical Infectious Diseases, 2002, 34, 831-837.	5.8	678
7	Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clinical Infectious Diseases, 2018, 67, 1477-1492.	5.8	509
8	Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVIDâ€19 Pandemic: AASLD Expert Panel Consensus Statement. Hepatology, 2020, 72, 287-304.	7.3	408
9	Comprehensive serological profiling of human populations using a synthetic human virome. Science, 2015, 348, aaa0698.	12.6	364
10	Circulating Mitochondrial DNA in Patients in the ICU as a Marker of Mortality: Derivation and Validation. PLoS Medicine, 2013, 10, e1001577.	8.4	354
11	Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naÃ¯ve patients. Hepatology, 2008, 48, 1769-1778.	7.3	326
12	Sofosbuvir and Ribavirin Prevent Recurrence of HCV Infection After Liver Transplantation: An Open-Label Study. Gastroenterology, 2015, 148, 100-107.e1.	1.3	307
13	Hepatic transferrin plays a role in systemic iron homeostasis and liver ferroptosis. Blood, 2020, 136, 726-739.	1.4	297
14	Hepatocyte TAZ/WWTR1 Promotes Inflammation and Fibrosis in Nonalcoholic Steatohepatitis. Cell Metabolism, 2016, 24, 848-862.	16.2	279
15	Safety and efficacy of sofosbuvirâ€containing regimens in hepatitis Câ€infected patients with impaired renal function. Liver International, 2016, 36, 807-816.	3.9	270
16	POSTTRANSPLANT DIABETES MELLITUS IN LIVER TRANSPLANT RECIPIENTS: RISK FACTORS, TEMPORAL RELATIONSHIP WITH HEPATITIS C VIRUS ALLOGRAFT HEPATITIS, AND IMPACT ON MORTALITY1. Transplantation, 2001, 72, 1066-1072.	1.0	257
17	Apolipoprotein B-dependent hepatitis C virus secretion is inhibited by the grapefruit flavonoid naringenin. Hepatology, 2008, 47, 1437-1445.	7.3	226
18	Treatment of hepatitis C virusâ€“associated mixed cryoglobulinemia with directâ€acting antiviral agents. Hepatology, 2016, 63, 408-417.	7.3	226

#	Article	IF	Citations
19	Genome-wide identification of microRNAs regulating cholesterol and triglyceride homeostasis. Nature Medicine, 2015, 21, 1290-1297.	30.7	214
20	Hepatic Injury in Nonalcoholic Steatohepatitis Contributes to Altered Intestinal Permeability. Cellular and Molecular Gastroenterology and Hepatology, 2015, 1, 222-232.e2.	4.5	209
21	Association of Aspirin with Hepatocellular Carcinoma and Liver-Related Mortality. New England Journal of Medicine, 2020, 382, 1018-1028.	27.0	208
22	Curing Chronic Hepatitis C â€" The Arc of a Medical Triumph. New England Journal of Medicine, 2014, 370, 1576-1578.	27.0	203
23	Prognostic Gene Expression Signature for Patients With Hepatitis Câ€"Related Early-Stage Cirrhosis. Gastroenterology, 2013, 144, 1024-1030.	1.3	195
24	Viral RNA Mutations Are Region Specific and Increased by Ribavirin in a Full-Length Hepatitis C Virus Replication System. Journal of Virology, 2002, 76, 8505-8517.	3.4	187
25	Genome-Wide Association Study of Spontaneous Resolution of Hepatitis C Virus Infection: Data From Multiple Cohorts. Annals of Internal Medicine, 2013, 158, 235.	3.9	187
26	Epidermal Growth Factor Gene Functional Polymorphism and the Risk of Hepatocellular Carcinoma in Patients With Cirrhosis. JAMA - Journal of the American Medical Association, 2008, 299, 53-60.	7.4	183
27	Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma. Journal of Hepatology, 2014, 61, S79-S90.	3.7	181
28	Hepatitis C Virus Regulates Transforming Growth Factor Î²1 Production Through the Generation of Reactive Oxygen Species in a Nuclear Factor ÎºBâ€"Dependent Manner. Gastroenterology, 2010, 138, 2509-2518.e1.	1.3	177
29	Antiviral treatment of hepatitis C. BMJ, The, 2014, 349, g3308-g3308.	6.0	175
30	Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition. Cancer Cell, 2016, 30, 879-890.	16.8	172
31	Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis. Cancer, 2007, 109, 2490-2496.	4.1	170
32	Association Between Aspirin Use and Risk of Hepatocellular Carcinoma. JAMA Oncology, 2018, 4, 1683.	7.1	170
33	Hepatitis C virus infection and its clearance alter circulating lipids: Implications for long-term follow-up. Hepatology, 2009, 50, 1030-1037.	7.3	169
34	Hepatitis C Virus Core Protein Blocks Interferon Signaling by Interaction with the STAT1 SH2 Domain. Journal of Virology, 2006, 80, 9226-9235.	3.4	167
35	Renal Thrombotic Microangiopathy Associated with Anticardiolipin Antibodies in Hepatitis C-Positive Renal Allograft Recipients. Journal of the American Society of Nephrology: JASN, 1999, 10, 146-153.	6.1	167
36	Liver Biochemistries in Hospitalized Patients With COVIDâ€19. Hepatology, 2021, 73, 890-900.	7.3	157

#	Article	IF	Citations
37	Coinfection With HIV-1 and HCVâ€"A One-Two Punch. Gastroenterology, 2009, 137, 795-814.	1.3	152
38	Bi-directional analysis between fatty liver and cardiovascular disease risk factors. Journal of Hepatology, 2017, 66, 390-397.	3.7	152
39	HCV and HIV co-infection: mechanisms and management. Nature Reviews Gastroenterology and Hepatology, 2014, 11, 362-371.	17.8	148
40	Atorvastatin and fluvastatin are associated with doseâ€dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES. Hepatology, 2016, 64, 47-57.	7.3	147
41	Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects. Aids, 2002, 16, 1915-1923.	2.2	146
42	Hepatitis C virus expression suppresses interferon signaling by degrading STAT1. Gastroenterology, 2005, 128, 1034-1041.	1.3	141
43	Macrophage MerTK Promotes Liver Fibrosis in Nonalcoholic Steatohepatitis. Cell Metabolism, 2020, 31, 406-421.e7.	16.2	141
44	The shortâ€term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with directâ€acting antivirals: An ERCHIVES study. Hepatology, 2018, 67, 2244-2253.	7.3	137
45	American Association for the Study of Liver Diseases Expert Panel Consensus Statement: Vaccines to Prevent Coronavirus Disease 2019 Infection in Patients With Liver Disease. Hepatology, 2021, 74, 1049-1064.	7.3	136
46	A Functional Polymorphism in the Epidermal Growth Factor Gene Is Associated With Risk for Hepatocellular Carcinoma. Gastroenterology, 2011, 141, 141-149.	1.3	133
47	An RNA-based signature enables high specificity detection of circulating tumor cells in hepatocellular carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 1123-1128.	7.1	133
48	HIV Increases HCV Replication in a TGF-Î²1â€"Dependent Manner. Gastroenterology, 2008, 134, 803-811.	1.3	132
49	Spontaneous Control of HCV Is Associated With Expression of HLA-B*57 and Preservation of Targeted Epitopes. Gastroenterology, 2011, 140, 686-696.e1.	1.3	130
50	Liver transplantation outcomes for early-stage hepatocellular carcinoma: Results of a multicenter study. Liver Transplantation, 2004, 10, 1343-1354.	2.4	126
51	Hepatitis C Disease Burden in the United States in the era of oral directâ€acting antivirals. Hepatology, 2016, 64, 1442-1450.	7.3	126
52	Development of an Accurate Index for Predicting Outcomes of Patients With Acute Liver Failure. Gastroenterology, 2012, 143, 1237-1243.	1.3	125
53	Cost-Effectiveness of Risk Scoreâ€"Stratified Hepatocellular Carcinoma Screening in Patients with Cirrhosis. Clinical and Translational Gastroenterology, 2017, 8, e101.	2.5	124
54	Epigenetic scars of CD8+ T cell exhaustion persist after cure of chronic infection in humans. Nature Immunology, 2021, 22, 1020-1029.	14.5	124

#	Article	IF	Citations
55	Naringenin inhibits the assembly and long-term production of infectious hepatitis C virus particles through a PPAR-mediated mechanism. Journal of Hepatology, 2011, 55, 963-971.	3.7	121
56	IL28B inhibits hepatitis C virus replication through the JAKâ€“STAT pathway. Journal of Hepatology, 2011, 55, 289-298.	3.7	120
57	B-cell depletion attenuates serological biomarkers of fibrosis and myofibroblast activation in IgG4-related disease. Annals of the Rheumatic Diseases, 2015, 74, 2236-2243.	0.9	120
58	Hepatitis C virus is independently associated with increased insulin resistance after liver transplantation. Transplantation, 2004, 77, 703-710.	1.0	112
59	The magnitude and breadth of hepatitis C virusâ€“specific CD8+ T cells depend on absolute CD4+ T-cell count in individuals coinfected with HIV-1. Blood, 2005, 105, 1170-1178.	1.4	110
60	Pharmacological Inhibition of a MicroRNA Family in Nonhuman Primates by a Seed-Targeting 8-Mer AntimiR. Science Translational Medicine, 2013, 5, 212ra162.	12.4	109
61	Hepatitis C virus leaves an epigenetic signature post cure of infection by direct-acting antivirals. PLoS Genetics, 2019, 15, e1008181.	3.5	109
62	Daily Aspirin Use Associated With Reduced Risk For Fibrosis Progression In Patients With Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 2019, 17, 2776-2784.e4.	4.4	108
63	Atorvastatin does not exhibit antiviral activity against HCV at conventional doses: A pilot clinical trial. Hepatology, 2007, 45, 895-898.	7.3	105
64	Prognosis of Patients with Cirrhosis and AKI Who Initiate RRT. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 16-25.	4.5	103
65	Kinetic differences in the induction of interferon stimulated genes by interferon-Î± and interleukin 28B are altered by infection with hepatitis C virus. Hepatology, 2014, 59, 1250-1261.	7.3	102
66	Human Immunodeficiency Virus Type 1-Hepatitis C Virus Coinfection: Intraindividual Comparison of Cellular Immune Responses against Two Persistent Viruses. Journal of Virology, 2002, 76, 2817-2826.	3.4	101
67	Diabetes, metabolic comorbidities, and risk of hepatocellular carcinoma: Results from two prospective cohort studies. Hepatology, 2018, 67, 1797-1806.	7.3	100
68	Pegylated interferon alpha-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C. Clinical Transplantation, 2004, 18, 166-173.	1.6	99
69	HIV and HCV Cooperatively Promote Hepatic Fibrogenesis via Induction of Reactive Oxygen Species and NFÎºB. Journal of Biological Chemistry, 2011, 286, 2665-2674.	3.4	99
70	Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients. Gastroenterology, 2005, 128, 313-327.	1.3	97
71	Statin use is associated with a reduced risk of fibrosis progression in chronic hepatitis C. Journal of Hepatology, 2015, 62, 18-23.	3.7	96
72	Lipophilic Statins and Risk for Hepatocellular Carcinoma and Death in Patients With Chronic Viral Hepatitis: Results From a Nationwide Swedish Population. Annals of Internal Medicine, 2019, 171, 318.	3.9	95

#	Article	IF	Citations
73	Effect of addition of statins to antiviral therapy in hepatitis C virusâ€“infected persons: Results from ERCHIVES. Hepatology, 2015, 62, 365-374.	7.3	91
74	Improving the Diagnosis of Acute Hepatitis C Virus Infection with Expanded Viral Load Criteria. Clinical Infectious Diseases, 2009, 49, 1051-1060.	5.8	90
75	Approach to the Management of Allograft Recipients Following the Detection of Hepatitis B Virus in the Prospective Organ Donor. American Journal of Transplantation, 2001, 1, 185-191.	4.7	86
76	A Cell-Based, High-Throughput Screen for Small Molecule Regulators of Hepatitis C Virus Replication. Gastroenterology, 2007, 132, 311-320.	1.3	86
77	Roles of Iron and HFE Mutations on Severity and Response to Therapy During Retreatment of Advanced Chronic Hepatitis C. Gastroenterology, 2006, 131, 1440-1451.	1.3	83
78	Antiâ^'Hepatitis C Virus Drugs in Development. Gastroenterology, 2012, 142, 1340-1350.e1.	1.3	83
79	Optimal timing of hepatitis C treatment for patients on the liver transplant waiting list. Hepatology, 2017, 65, 777-788.	7.3	83
80	Hepatitis C virus acts as a tumor accelerator by blocking apoptosis in a mouse model of hepatocarcinogenesis. Hepatology, 2005, 41, 660-667.	7.3	80
81	Reduction of Insulin Resistance With Effective Clearance of Hepatitis C Infection: Results From the HALT-C Trial. Clinical Gastroenterology and Hepatology, 2010, 8, 458-462.	4.4	80
82	Overview of Direct-Acting Antiviral Drugs and Drug Resistance of Hepatitis C Virus. Methods in Molecular Biology, 2019, 1911, 3-32.	0.9	80
83	Hepatitis C Virusâ€“Associated Cancer. Annual Review of Pathology: Mechanisms of Disease, 2015, 10, 345-370.	22.4	79
84	Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection. PLoS ONE, 2016, 11, e0158431.	2.5	79
85	Detection of Hepatitis C Virus (HCV) in Serum and Peripheralâ€Blood Mononuclear Cells from HCVâ€Monoinfected and HIV/HCVâ€“Coinfected Persons. Journal of Infectious Diseases, 2005, 192, 258-265.	4.0	78
86	Bariatric surgery for nonalcoholic steatohepatitis: A clinical and costâ€effectiveness analysis. Hepatology, 2017, 65, 1156-1164.	7.3	76
87	Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology, 2009, 49, 1847-1858.	7.3	75
88	The effect of angiotensinâ€blocking agents on liver fibrosis in patients with hepatitis C. Liver International, 2009, 29, 748-753.	3.9	75
89	Tyrosine kinase SYK is a potential therapeutic target for liver fibrosis. Hepatology, 2018, 68, 1125-1139.	7.3	74
90	Hepatitis C Virus NS5A Disrupts STAT1 Phosphorylation and Suppresses Type I Interferon Signaling. Journal of Virology, 2012, 86, 8581-8591.	3.4	73

#	Article	IF	Citations
91	Targeting acid ceramidase inhibits YAP/TAZ signaling to reduce fibrosis in mice. Science Translational Medicine, 2020, 12, .	12.4	71
92	Mutations in the NS5A region do not predict interferon-responsiveness in American patients infected with genotype 1b hepatitis C virus. Journal of Medical Virology, 1999, 58, 353-358.	5.0	70
93	A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration. Gut, 2015, 64, 1296-1302.	12.1	70
94	Direct-Acting Antiviral Therapy for Chronic HCV Infection Results in Liver Stiffness Regression Over 12ÂMonths Post-treatment. Digestive Diseases and Sciences, 2018, 63, 486-492.	2.3	69
95	Screening for Nonalcoholic Steatohepatitis in Individuals with Type 2 Diabetes: A Cost-Effectiveness Analysis. Digestive Diseases and Sciences, 2016, 61, 2108-2117.	2.3	67
96	Barriers to Use of Palliative Care and Advance Care Planning Discussions for Patients With End-Stage Liver Disease. Clinical Gastroenterology and Hepatology, 2019, 17, 2592-2599.	4.4	67
97	Prognosis of Acute Kidney Injury and Hepatorenal Syndrome in Patients with Cirrhosis: A Prospective Cohort Study. International Journal of Nephrology, 2015, 2015, 1-9.	1.3	66
98	HCV induces transforming growth factor Î²1 through activation of endoplasmic reticulum stress and the unfolded protein response. Scientific Reports, 2016, 6, 22487.	3.3	66
99	Pre-emptive pangenotypic direct acting antiviral therapy in donor HCV-positive to recipient HCV-negative heart transplantation: an open-label study. The Lancet Gastroenterology and Hepatology, 2019, 4, 771-780.	8.1	66
100	Serum Apoptosis Markers in Acute Liver Failure: A Pilot Study. Clinical Gastroenterology and Hepatology, 2007, 5, 1477-1483.	4.4	63
101	Impact of hepatitis <scp>C</scp> virus eradication on hepatocellular carcinogenesis. Cancer, 2015, 121, 2874-2882.	4.1	63
102	Use of sofosbuvir-based direct-acting antiviral therapy for hepatitis C viral infection in patients with severe renal insufficiency. Infectious Diseases, 2015, 47, 924-929.	2.8	63
103	Differentiation of exhausted CD8+ T cells after termination of chronic antigen stimulation stops short of achieving functional T cell memory. Nature Immunology, 2021, 22, 1030-1041.	14.5	63
104	Rapidly progressive fibrosing cholestatic hepatitis-hepatitis C virus in HIV coinfection. American Journal of Gastroenterology, 2002, 97, 478-483.	0.4	62
105	Should we treat acute hepatitis C? A decision and costâ€effectiveness analysis. Hepatology, 2018, 67, 837-846.	7.3	61
106	A functional genomic screen reveals novel host genes that mediate interferon-alphaâ€™s effects against hepatitis C virus. Journal of Hepatology, 2012, 56, 326-333.	3.7	60
107	Hepatitis B-related outcomes following direct-acting antiviral therapy in Taiwanese patients with chronic HBV/HCV co-infection. Journal of Hepatology, 2020, 73, 62-71.	3.7	60
108	Twoâ€year outcomes in initial survivors with acute liver failure: results from a prospective, multicentre study. Liver International, 2015, 35, 370-380.	3.9	59

#	Article	IF	Citations
109	Long noncoding RNAs expressed in human hepatic stellate cells form networks with extracellular matrix proteins. Genome Medicine, 2016, 8, 31.	8.2	59
110	The Effects of Angiotensin Blocking Agents on the Progression of Liver Fibrosis in the HALT-C Trial Cohort. Digestive Diseases and Sciences, 2011, 56, 564-568.	2.3	58
111	A YAP/TAZ-miR-130/301 molecular circuit exerts systems-level control of fibrosis in a network of human diseases and physiologic conditions. Scientific Reports, 2015, 5, 18277.	3.3	58
112	Gc-globulin and prognosis in acute liver failure. Liver Transplantation, 2005, 11, 1223-1227.	2.4	57
113	Influence of High Body Mass Index on Outcome in Acute Liver Failure. Clinical Gastroenterology and Hepatology, 2006, 4, 1544-1549.	4.4	57
114	Hepatic SOCS3 expression is strongly associated with non-response to therapy and race in HCV and HCV/HIV infection. Journal of Hepatology, 2009, 50, 705-711.	3.7	57
115	ARF1 and GBF1 Generate a PI4P-Enriched Environment Supportive of Hepatitis C Virus Replication. PLoS ONE, 2012, 7, e32135.	2.5	57
116	Poor Adherence to AASLD Guidelines for Chronic Hepatitis B Management and Treatment in a Large Academic Medical Center. American Journal of Gastroenterology, 2014, 109, 867-875.	0.4	57
117	Urinary NGAL as a Diagnostic and Prognostic Marker for Acute Kidney Injury in Cirrhosis: A Prospective Study. Clinical and Translational Gastroenterology, 2021, 12, e00359.	2.5	57
118	GB Virus C (GBVâ€C) Infection in Hepatitis C Virus (HCV)/HIVâ€“Coinfected Patients Receiving HCV Treatment: Importance of the GBVâ€C Genotype. Journal of Infectious Diseases, 2006, 194, 410-419.	4.0	56
119	Prospective study of liver transplant recipients with HCV infection: Evidence for a causal relationship between HCV and insulin resistance. Liver Transplantation, 2008, 14, 193-201.	2.4	56
120	Multicenter Study to Transplant Hepatitis Câ€“Infected Kidneys (MYTHIC): An Open-Label Study of Combined Glecaprevir and Pibrentasvir to Treat Recipients of Transplanted Kidneys from Deceased Donors with Hepatitis C Virus Infection. Journal of the American Society of Nephrology: JASN, 2020, 31, 2678-2687.	6.1	55
121	T2 relaxation time is related to liver fibrosis severity. Quantitative Imaging in Medicine and Surgery, 2016, 6, 103-114.	2.0	54
122	Chronic hepatitis C infectionâ€“induced liver fibrogenesis is associated with M2 macrophage activation. Scientific Reports, 2016, 6, 39520.	3.3	53
123	Circulating Interleukin-6 is a biomarker for coronary atherosclerosis in nonalcoholic fatty liver disease: Results from the Multi-Ethnic Study of Atherosclerosis. International Journal of Cardiology, 2018, 259, 198-204.	1.7	53
124	Short and Long-Term Outcomes in Patients with Acute Liver Failure Due to Ischemic Hepatitis. Digestive Diseases and Sciences, 2012, 57, 777-785.	2.3	52
125	Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients WithÂHepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 Trial. Gastroenterology, 2016, 151, 902-909.	1.3	52
126	Evolution of hepatic steatosis in patients with advanced hepatitis C: Results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. Hepatology, 2009, 49, 1828-1837.	7.3	51

#	Article	IF	Citations
127	Monitoring during and after antiviral therapy for hepatitis B. Hepatology, 2009, 49, S166-S173.	7.3	51
128	The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe. International Journal of Cardiology, 2018, 270, 245-252.	1.7	51
129	Treatment failure in hepatitis C: Mechanisms of non-response. Journal of Hepatology, 2009, 50, 412-420.	3.7	50
130	HIV infection increases HCV-induced hepatocyte apoptosis. Journal of Hepatology, 2011, 54, 612-620.	3.7	50
131	Early Transcriptional Divergence Marks Virus-Specific Primary Human CD8+ T Cells in Chronic versus Acute Infection. Immunity, 2017, 47, 648-663.e8.	14.3	50
132	Transplanting hepatitis C virusâ€“positive livers into hepatitis C virusâ€“negative patients with preemptive antiviral treatment: A modeling study. Hepatology, 2018, 67, 2085-2095.	7.3	50
133	Hepatic gap junctions amplify alcohol liver injury by propagating cGAS-mediated IRF3 activation. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 11667-11673.	7.1	50
134	Hepatic Fibrosis Associates With Multiple Cardiometabolic Disease Risk Factors: The Framingham Heart Study. Hepatology, 2021, 73, 548-559.	7.3	49
135	De Novo Autoimmune Hepatitis during Immune Reconstitution in an HIV-Infected Patient Receiving Highly Active Antiretroviral Therapy. Clinical Infectious Diseases, 2008, 46, e12-e14.	5.8	48
136	HCV and Host Lipids: An Intimate Connection. Seminars in Liver Disease, 2013, 33, 358-368.	3.6	48
137	Heat stroke leading to acute liver injury & failure: A case series from the Acute Liver Failure Study Group. Liver International, 2017, 37, 509-513.	3.9	48
138	Spontaneous resolution of chronic hepatitis C virus disease after withdrawal of immunosuppression. Gastroenterology, 2003, 124, 1946-1949.	1.3	47
139	Compartmentalization of Hepatitis C Virus (HCV) during HCV/HIV Coinfection. Journal of Infectious Diseases, 2007, 195, 1765-1773.	4.0	47
140	Direct-acting antiviral treatment for hepatitis C. Lancet, The, 2019, 393, 1392-1394.	13.7	47
141	Hepatic Steatosis in Hepatitis C: Comparison of Diabetic and Nondiabetic Patients in the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial. Clinical Gastroenterology and Hepatology, 2007, 5, 245-254.	4.4	46
142	Obstructive Sleep Apnea Is Associated with Nonalcoholic Steatohepatitis and Advanced Liver Histology. Digestive Diseases and Sciences, 2015, 60, 2523-2528.	2.3	46
143	Direct-acting antiviral therapy for hepatitis C virus infection in the kidney transplant recipient. Kidney International, 2018, 93, 560-567.	5.2	46
144	A MicroRNA Linking Human Positive Selection and Metabolic Disorders. Cell, 2020, 183, 684-701.e14.	28.9	46

#	Article	IF	Citations
145	Changes in Kidney Function After Transjugular Intrahepatic Portosystemic Shunts Versus Large-Volume Paracentesis in Cirrhosis: A Matched Cohort Analysis. American Journal of Kidney Diseases, 2016, 68, 381-391.	1.9	45
146	A Long Noncoding RNA Regulates Hepatitis C Virus Infection Through Interferon Alphaâ€“Inducible Protein 6. Hepatology, 2019, 69, 1004-1019.	7.3	45
147	Hospital readmissions in decompensated cirrhotics: Factors pointing toward a prevention strategy. World Journal of Gastroenterology, 2017, 23, 6868-6876.	3.3	45
148	Hepatitis B reactivation during or after direct acting antiviral therapy â€“ implication for susceptible individuals. Expert Opinion on Drug Safety, 2017, 16, 651-672.	2.4	44
149	Most ApoL1 Is Secreted by the Liver. Journal of the American Society of Nephrology: JASN, 2017, 28, 1079-1083.	6.1	44
150	Direct-acting antiviral therapy slows kidney function decline in patients with Hepatitis C virus infection and chronic kidney disease. Kidney International, 2020, 97, 193-201.	5.2	44
151	Hepatitis C treatment: an incipient therapeutic revolution. Trends in Molecular Medicine, 2014, 20, 315-321.	6.7	42
152	Hepatitis C virus <scp>NS</scp>5A drives a <scp>PTEN</scp>â€<scp>PI</scp>3K/Akt feedback loop to support cell survival. Liver International, 2015, 35, 1682-1691.	3.9	42
153	Circulating Soluble CD163 is Associated with Steatohepatitis and Advanced Fibrosis in Nonalcoholic Fatty Liver Disease. Clinical and Translational Gastroenterology, 2015, 6, e114.	2.5	42
154	Sofosbuvir Plus Ribavirin Without Interferon for Treatment of Acute Hepatitis C Virus Infection in HIV-1â€“Infected Individuals: SWIFT-C. Clinical Infectious Diseases, 2017, 64, 1035-1042.	5.8	42
155	Suppressor of Cytokine Signaling 3 Suppresses Hepatitis C Virus Replication in an mTOR-Dependent Manner. Journal of Virology, 2010, 84, 6060-6069.	3.4	41
156	Lipid Metabolite Profiling Identifies Desmosterol Metabolism as a New Antiviral Target for Hepatitis C Virus. Journal of the American Chemical Society, 2012, 134, 6896-6899.	13.7	41
157	New perspectives for preventing hepatitis C virus liver graft infection. Lancet Infectious Diseases, The, 2016, 16, 735-745.	9.1	41
158	Physiciansâ€™ Perspectives on Palliative Care for Patients With Endâ€Stage Liver Disease: A National Survey Study. Liver Transplantation, 2019, 25, 859-869.	2.4	40
159	Mother-to-child transmission of hepatitis B virus in sub-Saharan Africa: time to act. The Lancet Global Health, 2015, 3, e358-e359.	6.3	39
160	Antiviral activity of bone morphogenetic proteins and activins. Nature Microbiology, 2019, 4, 339-351.	13.3	39
161	Virus detection using nanoparticles and deep neural networkâ€“enabled smartphone system. Science Advances, 2020, 6, .	10.3	39
162	Acute Hepatitis C Virus Infection. Clinical Infectious Diseases, 2005, 41, S14-S17.	5.8	38

#	Article	IF	Citations
163	HELZ2 Is an IFN Effector Mediating Suppression of Dengue Virus. Frontiers in Microbiology, 2017, 8, 240.	3.5	38
164	Serum Vitamin D Levels Are Not Predictive of the Progression of Chronic Liver Disease in Hepatitis C Patients with Advanced Fibrosis. PLoS ONE, 2012, 7, e27144.	2.5	38
165	A Genetic Screen Identifies Interferon-Î± Effector Genes Required to Suppress Hepatitis C Virus Replication. Gastroenterology, 2013, 144, 1438-1449.e9.	1.3	37
166	EFTUD2 Is a Novel Innate Immune Regulator Restricting Hepatitis C Virus Infection through the RIG-I/MDA5 Pathway. Journal of Virology, 2015, 89, 6608-6618.	3.4	37
167	Relations of Liver Fat With Prevalent and Incident Atrial Fibrillation in the Framingham Heart Study. Journal of the American Heart Association, 2017, 6, .	3.7	37
168	Entecavir and Peginterferon Alfaâ€2a in Adults With Hepatitis B e Antigenâ€“Positive Immuneâ€Tolerant Chronic Hepatitis B Virus Infection. Hepatology, 2019, 69, 2338-2348.	7.3	37
169	Health Care Utilization and End-of-Life Care Outcomes for Patients With Decompensated Cirrhosis Based on Transplant Candidacy. Journal of Pain and Symptom Management, 2020, 59, 590-598.	1.2	37
170	Novel Therapies for Hepatitis C: Insights from the Structure of the Virus. Annual Review of Medicine, 2012, 63, 373-387.	12.2	36
171	Exposure to human immunodeficiency virus/hepatitis C virus in hepatic and stellate cell lines reveals cooperative profibrotic transcriptional activation between viruses and cell types. Hepatology, 2016, 64, 1951-1968.	7.3	36
172	Macrophage Activation Marker Soluble CD163 Is a Dynamic Marker of Liver Fibrogenesis in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection. Journal of Infectious Diseases, 2018, 218, 1394-1403.	4.0	36
173	Comparison of HBV RNA and Hepatitis B Core Related Antigen With Conventional HBV Markers Among Untreated Adults With Chronic Hepatitis B in North America. Hepatology, 2021, 74, 2395-2409.	7.3	36
174	Molecular characterization and cell type composition deconvolution of fibrosis in NAFLD. Scientific Reports, 2021, 11, 18045.	3.3	36
175	Intrahepatic cytokine expression is downregulated during HCV/HIV co-infection. Journal of Medical Virology, 2006, 78, 202-207.	5.0	35
176	Direct-Acting Antiviral Agents and the Path to Interferon Independence. Clinical Gastroenterology and Hepatology, 2014, 12, 728-737.	4.4	34
177	A simple clinical model predicts incident hepatic steatosis in a communityâ€based cohort: The Framingham Heart Study. Liver International, 2018, 38, 1495-1503.	3.9	34
178	Expert Panel Review on Nonalcoholic Fatty Liver Disease in Persons With Human Immunodeficiency Virus. Clinical Gastroenterology and Hepatology, 2022, 20, 256-268.	4.4	34
179	Host-targeting agents for treatment of hepatitis B virus infection. Current Opinion in Virology, 2015, 14, 41-46.	5.4	33
180	Sofosbuvirâ€based regimens in clinical practice achieve <scp>SVR</scp> rates closer to clinical trials: results from <scp>ERCHIVES</scp>. Liver International, 2016, 36, 651-658.	3.9	33

#	Article	IF	Citations
181	Spectrum of Liver Disease in Hepatitis B Virus (HBV) Patients Co-infected with Human Immunodeficiency Virus (HIV): Results of the HBV-HIV Cohort Study. American Journal of Gastroenterology, 2019, 114, 746-757.	0.4	33
182	MicroRNA 130a Regulates both Hepatitis C Virus and Hepatitis B Virus Replication through a Central Metabolic Pathway. Journal of Virology, 2018, 92, .	3.4	32
183	Physical activity compared to adiposity and risk of liver-related mortality: Results from two prospective, nationwide cohorts. Journal of Hepatology, 2020, 72, 1062-1069.	3.7	32
184	NEPHROTIC SYNDROME AFTER LIVER TRANSPLANTATION IN A PATIENT WITH HEPATITIS C VIRUS-ASSOCIATED GLOMERULONEPHRITIS1. Transplantation, 1997, 64, 1073-1076.	1.0	32
185	Case 15-2006. New England Journal of Medicine, 2006, 354, 2166-2175.	27.0	31
186	Immediate administration of antiviral therapy after transplantation of hepatitis C-infected livers into uninfected recipients: Implications for therapeutic planning. American Journal of Transplantation, 2020, 20, 1619-1628.	4.7	31
187	A blood-based prognostic liver secretome signature and long-term hepatocellular carcinoma risk in advanced liver fibrosis. Med, 2021, 2, 836-850.e10.	4.4	31
188	Antigen-specific immune responses and liver histology in HIV and hepatitis C coinfection. Aids, 2005, 19, 767-773.	2.2	30
189	Lessons From HIV Therapy Applied to Viral Hepatitis Therapy: Summary of a Workshop. American Journal of Gastroenterology, 2010, 105, 989-1004.	0.4	30
190	Noninvasive Biomarkers of Liver Fibrosis: Clinical Applications and Future Directions. Current Pathobiology Reports, 2014, 2, 245-256.	3.4	30
191	Chronic Hepatitis C. Gut and Liver, 2011, 5, 117-132.	2.9	29
192	Hepatocellular Carcinoma Screening Rates Vary by Etiology of Cirrhosis and Involvement of Gastrointestinal Sub-specialists. Digestive Diseases and Sciences, 2011, 56, 3316-3322.	2.3	29
193	Diabetes and prediabetes in patients with hepatitis B residing in North America. Hepatology, 2015, 62, 1364-1374.	7.3	29
194	Enhancing Our Understanding of Current Therapies for Hepatitis C Virus (HCV). Current HIV/AIDS Reports, 2015, 12, 68-78.	3.1	29
195	Prevention of mother-to-child transmission of hepatitis B virus: a phase III, placebo-controlled, double-blind, randomized clinical trial to assess the efficacy and safety of a short course of tenofovir disoproxil fumarate in women with hepatitis B virus e-antigen. BMC Infectious Diseases, 2016, 16, 393.	2.9	29
196	Intermittent hypoxia is a proinflammatory stimulus resulting in ILâ€6 expression and M1 macrophage polarization. Hepatology Communications, 2017, 1, 326-337.	4.3	29
197	High Rates of Hepatitis B Virus (HBV) Functional Cure Among Human Immunodeficiency Virus-HBV Coinfected Patients on Antiretroviral Therapy in Zambia. Journal of Infectious Diseases, 2020, 221, 218-222.	4.0	29
198	Avoiding therapeutic pitfalls: The rational use of specifically targeted agents against hepatitis C infection. Hepatology, 2008, 48, 1700-1712.	7.3	28

#	Article	IF	Citations
199	The Effect of Hepatitis C Virologic Clearance on Cardiovascular Disease Biomarkers in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection. Open Forum Infectious Diseases, 2014, 1, ofu104.	0.9	28
200	A role for retromer in hepatitis C virus replication. Cellular and Molecular Life Sciences, 2016, 73, 869-881.	5.4	28
201	Fatty Acids Activate the Transcriptional Coactivator YAP1 to Promote Liver Fibrosis via p38 Mitogen-Activated Protein Kinase. Cellular and Molecular Gastroenterology and Hepatology, 2021, 12, 1297-1310.	4.5	28
202	Risk of Acute Myocardial Infarction Among Hepatitis C Virus (HCV)-Positive and HCV-Negative Men at Various Lipid Levels: Results From ERCHIVES. Clinical Infectious Diseases, 2017, 65, 557-565.	5.8	27
203	Treatment of hepatitis C virus infection in patients with mixed cryoglobulinemic syndrome and cryoglobulinemic glomerulonephritis. Hemodialysis International, 2018, 22, S81-S96.	0.9	27
204	Variability and Lability of Ammonia Levels in Healthy Volunteers and Patients With Cirrhosis: Implications for Trial Design and Clinical Practice. American Journal of Gastroenterology, 2020, 115, 783-785.	0.4	27
205	Prevalence of hepatitis C virus-associated mixed cryoglobulinemia after liver transplantation. Liver Transplantation, 2000, 6, 185-190.	2.4	26
206	Sustained Long-Term Antiviral Maintenance Therapy in HCV/HIV-Coinfected Patients (SLAM-C). Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 55, 597-605.	2.1	26
207	The AMPK-related kinase SNARK regulates hepatitis C virus replication and pathogenesis through enhancement of TGF-Î² signaling. Journal of Hepatology, 2013, 59, 942-948.	3.7	26
208	Lupus-Like Immune Complex-Mediated Glomerulonephritis in Patients WithÂHepatitis C Virus Infection Treated With Oral, Interferon-Free, Direct-Acting AntiviralÂTherapy. Kidney International Reports, 2016, 1, 135-143.	0.8	26
209	A Novel Resolvin-Based Strategy for Limiting Acetaminophen Hepatotoxicity. Clinical and Translational Gastroenterology, 2016, 7, e153.	2.5	26
210	Serum Angiopoietinâ€2 Predicts Mortality and Kidney Outcomes in Decompensated Cirrhosis. Hepatology, 2019, 69, 729-741.	7.3	26
211	Parental nonâ€alcoholic fatty liver disease increases risk of nonâ€alcoholic fatty liver disease in offspring. Liver International, 2019, 39, 740-747.	3.9	26
212	Modeling the Hepatology Workforce in the United States: A Predicted Critical Shortage. Hepatology, 2020, 72, 1444-1454.	7.3	26
213	Type I, II, and III Interferon Signatures Correspond to Coronavirus Disease 2019 Severity. Journal of Infectious Diseases, 2021, 224, 777-782.	4.0	26
214	Treatment adherence and virological response rates in hepatitis C virus infected persons treated with sofosbuvirâ€based regimens: results from <scp>ERCHIVES</scp>. Liver International, 2016, 36, 1275-1283.	3.9	25
215	Treatment of Hepatitis B: A Concise Review. Clinical and Translational Gastroenterology, 2016, 7, e190.	2.5	25
216	The spliceosome factor SART1 exerts its anti-HCV action through mRNA splicing. Journal of Hepatology, 2015, 62, 1024-1032.	3.7	24

#	Article	IF	Citations
217	Relationship between resolution of nonâ€alcoholic steatohepatitis and changes in lipoprotein subâ€fractions: a postâ€hoc analysis of the <scp>PIVENS</scp> trial. Alimentary Pharmacology and Therapeutics, 2019, 49, 1205-1213.	3.7	24
218	Cost Effectiveness of Transplanting HCV-Infected Livers Into Uninfected Recipients With Preemptive Antiviral Therapy. Clinical Gastroenterology and Hepatology, 2019, 17, 739-747.e8.	4.4	24
219	Evaluation of model performance to predict survival after transjugular intrahepatic portosystemic shunt placement. PLoS ONE, 2019, 14, e0217442.	2.5	23
220	Evaluating Noninvasive Markers to Identify Advanced Fibrosis by Liver Biopsy in HBV/HIV Coâ€infected Adults. Hepatology, 2020, 71, 411-421.	7.3	23
221	Gammaâ€Glutamyltransferase Elevation Is Frequent in Patients With COVIDâ€19: A Clinical Epidemiologic Study. Hepatology Communications, 2020, 4, 1744-1750.	4.3	23
222	Changes in circulating lipids level over time after acquiring HCV infection: results from ERCHIVES. BMC Infectious Diseases, 2015, 15, 510.	2.9	22
223	Using an Electronic Medical Records Database to Identify Non-Traditional Cardiovascular Risk Factors in Nonalcoholic Fatty Liver Disease. American Journal of Gastroenterology, 2016, 111, 671-676.	0.4	22
224	Tricyclic Antidepressants Promote Ceramide Accumulation to Regulate Collagen Production in Human Hepatic Stellate Cells. Scientific Reports, 2017, 7, 44867.	3.3	22
225	Terlipressin and the Treatment of Hepatorenal Syndrome: How the CONFIRM Trial Moves the Story Forward. American Journal of Kidney Diseases, 2022, 79, 737-745.	1.9	22
226	Fecal microbiota transplant improves cognition in hepatic encephalopathy and its effect varies by donor and recipient. Hepatology Communications, 2022, 6, 2079-2089.	4.3	22
227	Hepatitis C Virus in the HIV-Infected Patient. Clinics in Liver Disease, 2006, 10, 303-320.	2.1	21
228	Rate of Sustained Virologic Response in Relation to Baseline Hepatitis C Virus (HCV) RNA Level and Rapid Virologic Clearance in Persons with Acute HCV Infection. Journal of Infectious Diseases, 2009, 200, 877-881.	4.0	21
229	SOCS1 abrogates IFNâ€™s antiviral effect on hepatitis C virus replication. Antiviral Research, 2013, 97, 101-107.	4.1	21
230	Relationship Between Metabolic Syndrome, Alanine Aminotransferase Levels, and Liver Disease Severity in a Multiethnic North American Cohort With Chronic Hepatitis B. Diabetes Care, 2018, 41, 1251-1259.	8.6	21
231	Cost Effectiveness of Preâ€“ vs Postâ€“Liver Transplant Hepatitis C Treatment With Direct-Acting Antivirals. Clinical Gastroenterology and Hepatology, 2018, 16, 115-122.e10.	4.4	21
232	Use of Hepatitis C Positive Organs: Patient Attitudes in Urban Chicago. American Journal of Nephrology, 2019, 49, 32-40.	3.1	21
233	Dynamic changes in innate immune responses during directâ€acting antiviral therapy for <scp>HCV</scp> infection. Journal of Viral Hepatitis, 2019, 26, 362-372.	2.0	21
234	Mobile Health (mHealth) Viral Diagnostics Enabled with Adaptive Adversarial Learning. ACS Nano, 2021, 15, 665-673.	14.6	21

#	Article	IF	Citations
235	Inflammatory microenvironment of fibrotic liver promotes hepatocellular carcinoma growth, metastasis and sorafenib resistance through STAT3 activation. Journal of Cellular and Molecular Medicine, 2021, 25, 1568-1582.	3.6	21
236	A human liver cell-based system modeling a clinical prognostic liver signature for therapeutic discovery. Nature Communications, 2021, 12, 5525.	12.8	21
237	Management of hepatitis B reactivation in patients receiving cancer chemotherapy. Therapeutic Advances in Gastroenterology, 2012, 5, 359-370.	3.2	20
238	Dual Activators of Protein Kinase R (PKR) and Protein Kinase Râ€Like Kinase (PERK) Identify Common and Divergent Catalytic Targets. ChemBioChem, 2013, 14, 1255-1262.	2.6	20
239	Entry inhibitors and future treatment of hepatitis C. Antiviral Research, 2014, 104, 136-142.	4.1	20
240	Live cell imaging of cytosolic NADH/NAD⁺ratio in hepatocytes and liver slices. American Journal of Physiology - Renal Physiology, 2018, 314, G97-G108.	3.4	20
241	Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals. Clinical Infectious Diseases, 2019, 69, 514-522.	5.8	20
242	Hepatic Steatosis and Steatohepatitis in a Large North American Cohort of Adults With Chronic Hepatitis B. American Journal of Gastroenterology, 2021, 116, 1686-1697.	0.4	20
243	IL28B Alleles Exert an Additive Dose Effect When Applied to HCV-HIV Coinfected Persons Undergoing Peginterferon and Ribavirin Therapy. PLoS ONE, 2011, 6, e25753.	2.5	19
244	The Impact of Human Gene Polymorphisms on HCV Infection and Disease Outcome. Seminars in Liver Disease, 2011, 31, 375-386.	3.6	19
245	Development of proteinuria and focal segmental glomerulosclerosis during directâ€acting antiviral therapy for hepatitis C virus infection. Hepatology, 2017, 66, 658-660.	7.3	19
246	Validation of Shear Wave Elastography Cutoff Values on the Supersonic Aixplorer for Practical Clinical Use in Liver Fibrosis Staging. Ultrasound in Medicine and Biology, 2017, 43, 1125-1133.	1.5	19
247	IRGMGene Variants Modify the Relationship Between Visceral Adipose Tissue and NAFLD in Patients With Crohnâ€™s Disease. Inflammatory Bowel Diseases, 2018, 24, 2247-2257.	1.9	19
248	Outcomes of Palliative Care Consultations for Hospitalized Patients With Liver Disease. Journal of Pain and Symptom Management, 2019, 58, 766-773.	1.2	19
249	Microrna-130a Downregulates HCV Replication through an atg5-Dependent Autophagy Pathway. Cells, 2019, 8, 338.	4.1	19
250	Burdensome Transitions of Care for Patients with End-Stage Liver Disease and Their Caregivers. Digestive Diseases and Sciences, 2021, 66, 2942-2955.	2.3	19
251	Association of Statins and 28-Day Mortality Rates in Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Journal of Infectious Diseases, 2022, 225, 19-29.	4.0	19
252	Advanced Disease, Diuretic Use, and Marital Status Predict Hospital Admissions in an Ambulatory Cirrhosis Cohort. Digestive Diseases and Sciences, 2014, 59, 174-182.	2.3	18

#	Article	IF	Citations
253	Patients With Cirrhosis Require More Fecal Microbiota CapsulesÂto Cure Refractory and Recurrent Clostridium difficileÂInfections. Clinical Gastroenterology and Hepatology, 2019, 17, 791-793.	4.4	18
254	Deep stool microbiome analysis in cirrhosis reveals an association between short-chain fatty acids and hepatic encephalopathy. Annals of Hepatology, 2021, 25, 100333.	1.5	18
255	Hepatitis C Virus (HCV) Quasispecies Complexity and Selection in HCV/HIVâ€Coinfected Subjects Treated with Interferonâ€Based Regimens. Journal of Infectious Diseases, 2010, 201, 100127142343070-000.	4.0	17
256	Amyloidosis of the liver on shear wave elastography: case report and review of literature. Abdominal Imaging, 2015, 40, 3078-3083.	2.0	17
257	Outcomes of inâ€hospital cardiopulmonary resuscitation for patients with endâ€stage liver disease. Liver International, 2019, 39, 1256-1262.	3.9	17
258	Clinical Research in Hepatology in the COVIDâ€19 Pandemic and Postâ€Pandemic Era: Challenges and the Need for Innovation. Hepatology, 2020, 72, 1819-1837.	7.3	17
259	[18F]-Alfatide PET imaging of integrin Î±vÎ²3 for the non-invasive quantification of liver fibrosis. Journal of Hepatology, 2020, 73, 161-169.	3.7	17
260	Patient and Caregiver Perspectives on Palliative Care in End-Stage Liver Disease. Journal of Palliative Medicine, 2021, 24, 719-724.	1.1	17
261	Peptide-based urinary monitoring of fibrotic nonalcoholic steatohepatitis by mass-barcoded activity-based sensors. Science Translational Medicine, 2021, 13, eabe8939.	12.4	17
262	Molecular Signature Predictive of Long-Term Liver Fibrosis Progression to Inform Antifibrotic Drug Development. Gastroenterology, 2022, 162, 1210-1225.	1.3	17
263	IQGAP2 is a novel interferon-alpha antiviral effector gene acting non-conventionally through the NF-ÎºB pathway. Journal of Hepatology, 2016, 65, 972-979.	3.7	16
264	Preemptive Treatment With Elbasvir and Grazoprevir for Hepatitis Câ€“Viremic Donor to Uninfected Recipient Kidney Transplantation. Kidney International Reports, 2020, 5, 459-467.	0.8	16
265	Case 33-2006. New England Journal of Medicine, 2006, 355, 1812-1819.	27.0	15
266	Hematologic Toxicity Associated with Interferon-Based Hepatitis C Therapy in HIV Type 1-Coinfected Subjects. Clinical Infectious Diseases, 2007, 44, 1375-1383.	5.8	15
267	Racial Disparities in Inhospital Outcomes for Hepatocellular Carcinoma in the United States. Mayo Clinic Proceedings, 2016, 91, 1173-1182.	3.0	15
268	Association Between Plasma Level of Galectin-9 and Survival of Patients With Drug-Induced Acute Liver Failure. Clinical Gastroenterology and Hepatology, 2016, 14, 606-612.e3.	4.4	15
269	Effects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV/HCV-coinfected individuals receiving tenofovir disoproxil fumarate. Journal of Antimicrobial Chemotherapy, 2018, 73, 2112-2119.	3.0	15
270	Fatty Liver Disease in a Prospective North American Cohort of Adults With Human Immunodeficiency Virus and Hepatitis B Virus Coinfection. Clinical Infectious Diseases, 2021, 73, e3275-e3285.	5.8	15

#	Article	IF	Citations
271	Relationships between cellular immune responses and treatment outcomes with interferon and ribavirin in HIV/hepatitis C virus co-infection. Aids, 2006, 20, 345-351.	2.2	14
272	Impact of Peginterferon Alpha and Ribavirin Treatment on Lipid Profiles and Insulin Resistance in Hepatitis C Virus/HIV-Coinfected Persons: The AIDS Clinical Trials Group A5178 Study. Clinical Infectious Diseases, 2012, 55, 631-638.	5.8	14
273	Inhibition of HCV by the serpin antithrombin III. Virology Journal, 2012, 9, 226.	3.4	14
274	The Absence of Obstructive Sleep Apnea May Protect against Non-Alcoholic Fatty Liver in Patients Undergoing Bariatric Surgery. PLoS ONE, 2013, 8, e62504.	2.5	14
275	Cardiovascular Risk Reduction in Patients with Nonalcoholic Fatty Liver Disease: The Potential Role of Ezetimibe. Digestive Diseases and Sciences, 2016, 61, 3425-3435.	2.3	14
276	Insights Into the Pathophysiology of Liver Disease in HCV/HIV: Does it End With HCV Cure?. Journal of Infectious Diseases, 2020, 222, S802-S813.	4.0	14
277	No evidence for higher rates of hepatocellular carcinoma after direct-acting antiviral treatment: a meta-analysis. Hepatoma Research, 2019, 2019, .	1.5	14
278	Effects of HCV Treatment on Cytokine Expression During HCV/HIV Coinfection. Journal of Interferon and Cytokine Research, 2006, 26, 834-838.	1.2	13
279	Treatment of Type II Cryoglobulinemia Associated With Hepatitis C With Rituximab. Journal of Clinical Gastroenterology, 2006, 40, 450.	2.2	13
280	New protease inhibitors for HCV â€“ Help is on the way. Journal of Hepatology, 2011, 54, 1087-1089.	3.7	13
281	Benefits of Direct-Acting Antivirals for Hepatitis C. Annals of Internal Medicine, 2017, 167, 812.	3.9	13
282	Incidence and prediction of HBsAg seroclearance in a prospective multiâ€ethnic HBeAgâ€negative chronic hepatitis B cohort. Hepatology, 2022, 75, 709-723.	7.3	13
283	Extrahepatic hepatitis C virus after transplantation: Diabetes and renal dysfunction. Liver Transplantation, 2008, 14, S51-S57.	2.4	12
284	TRAIL Enhances Apoptosis of Human Hepatocellular Carcinoma Cells Sensitized by Hepatitis C Virus Infection: Therapeutic Implications. PLoS ONE, 2014, 9, e98171.	2.5	12
285	Association of donor hepatitis C virus infection status and risk of BK polyomavirus viremia after kidney transplantation. American Journal of Transplantation, 2022, 22, 599-609.	4.7	12
286	One-Year Outcomes of the Multi-Center StudY to Transplant Hepatitis C-InfeCted kidneys (MYTHIC) Trial. Kidney International Reports, 2022, 7, 241-250.	0.8	12
287	Hepatitis B and Hepatitis C Virus Infection Promote Liver Fibrogenesis through a TGF-Î²1â€“Induced OCT4/Nanog Pathway. Journal of Immunology, 2022, 208, 672-684.	0.8	12
288	Atorvastatin favorably modulates a clinical hepatocellular carcinoma risk gene signature. Hepatology Communications, 2022, 6, 2581-2593.	4.3	12

#	Article	IF	Citations
289	Extended Therapy With Pegylated Interferon and Weight-Based Ribavirin for HCV-HIV Coinfected Patients. HIV Clinical Trials, 2012, 13, 70-82.	2.0	11
290	IDSA/AASLD Response to Cochrane Review on Direct-Acting Antivirals for Hepatitis C. Clinical Infectious Diseases, 2017, 65, 1773-1775.	5.8	11
291	Use of proton pump inhibitors in chronic liver diseases. Clinical Liver Disease, 2017, 10, 148-151.	2.1	11
292	Transplantation of hepatitis C virus infected kidneys into hepatitis C virus uninfected recipients. Hemodialysis International, 2018, 22, S71-S80.	0.9	11
293	When and how can nephrologists treat hepatitis C virus infection in dialysis patients?. Seminars in Dialysis, 2018, 31, 26-36.	1.3	11
294	Precore and Basal Core Promoter Hepatitis B Virus (HBV) Variants Are Present From a Young Age and Differ Across HBV Genotypes. Hepatology, 2021, 73, 1637-1651.	7.3	11
295	[18F]MAGL-4-11 positron emission tomography molecular imaging of monoacylglycerol lipase changes in preclinical liver fibrosis models. Acta Pharmaceutica Sinica B, 2022, 12, 308-315.	12.0	11
296	A Prospective Study Evaluating Changes in Histology, Clinical and Virologic Outcomes in HBVâ€HIV Coâ€infected Adults in North America. Hepatology, 2021, 74, 1174-1189.	7.3	11
297	Risk of Cardiovascular Disease in Individuals With Nonobese Nonalcoholic Fatty Liver Disease. Hepatology Communications, 2022, 6, 309-319.	4.3	11
298	Host Genetics Predict Clinical Deterioration in HCV-Related Cirrhosis. PLoS ONE, 2014, 9, e114747.	2.5	11
299	Hepatic IRF3 fuels dysglycemia in obesity through direct regulation of Ppp2r1b. Science Translational Medicine, 2022, 14, eabh3831.	12.4	11
300	Persistent Cholestatic Injury and Secondary Sclerosing Cholangitis in COVID-19 Patients. Archives of Pathology and Laboratory Medicine, 2022, 146, 1184-1193.	2.5	11
301	Steroid-Responsive (Autoimmune?) Sclerosing Cholangitis. Digestive Diseases and Sciences, 2005, 50, 1839-1843.	2.3	10
302	Association of host pharmacodynamic effects with virologic response to pegylated interferon alfa-2a/ribavirin in chronic hepatitis C. Hepatology, 2010, 52, 1906-1914.	7.3	10
303	After the Cure: Management of HCV After Achievement of SVR. Current HIV/AIDS Reports, 2013, 10, 428-435.	3.1	10
304	Reduced Albumin Dosing During Large-Volume Paracentesis Is Not Associated with Adverse Clinical Outcomes. Digestive Diseases and Sciences, 2015, 60, 2190-2195.	2.3	10
305	Perspectives on HCV: Current Therapeutic Regimens and Drugâ€“Drug Interactions. Clinical Pharmacology in Drug Development, 2017, 6, 147-163.	1.6	10
306	Entry Inhibitors: A Perspective for Prevention of Hepatitis C Virus Infection in Organ Transplantation. ACS Infectious Diseases, 2017, 3, 620-623.	3.8	10

#	Article	IF	Citations
307	Diagnostic Accuracy of Shear Wave Elastography as a Non-invasive Biomarker of High-Risk Non-alcoholic Steatohepatitis in Patients with Non-alcoholic Fatty Liver Disease. Ultrasound in Medicine and Biology, 2020, 46, 972-980.	1.5	10
308	Hepatic Encephalopathy is Associated With Slow Speech on Objective Assessment. American Journal of Gastroenterology, 2021, 116, 1950-1953.	0.4	10
309	Viral Factors Associated with Cytokine Expression During HCV/HIV Co-Infection. Journal of Interferon and Cytokine Research, 2007, 27, 263-270.	1.2	9
310	The Dose-Response Relationship of Peginterferon Alfa-2a and Ribavirin in the Treatment of Patients Coinfected with HIV-HCV. HIV Clinical Trials, 2012, 13, 33-45.	2.0	9
311	One more piece in the interleukin 28B gene puzzle? The case of hepatitis B. Hepatology, 2013, 57, 870-872.	7.3	9
312	Optimal Antiviral Prophylaxis Against Hepatitis B Reactivation in Patients Receiving Rituximab-Based Chemotherapy for Lymphoma. JAMA - Journal of the American Medical Association, 2014, 312, 2505.	7.4	9
313	NAM 2017 report: A national plan to eliminate hepatitis B and C in the United States by 2030 and the AASLD's response. Hepatology, 2017, 66, 1020-1022.	7.3	9
314	Model for endâ€stage liver disease Na Score predicts incident major cardiovascular events in patients with nonalcoholic fatty liver disease. Hepatology Communications, 2017, 1, 429-438.	4.3	9
315	Opioid Use Disorder, Stigma, and Transplantation: A Call to Action. Annals of Internal Medicine, 2018, 169, 188.	3.9	9
316	Pilot Randomized Controlled Trial of an Advance Care Planning Video Decision Tool for Patients With Advanced Liver Disease. Clinical Gastroenterology and Hepatology, 2022, 20, 2287-2295.e3.	4.4	9
317	Tackling the hepatitis C cost problem: A test case for tomorrow's cures. Hepatology, 2015, 62, 1334-1336.	7.3	8
318	The new hepatitis C virus bottleneck: Can delaying therapy be justified?. Hepatology, 2015, 62, 666-667.	7.3	8
319	Siglec-7 as a Novel Biomarker to Predict Mortality in Decompensated Cirrhosis and Acute Kidney Injury. Digestive Diseases and Sciences, 2016, 61, 3609-3620.	2.3	8
320	Provider Attitudes toward the Use of Hepatitis C Virus-Positive Organs in Kidney Transplantation. American Journal of Nephrology, 2019, 50, 168-176.	3.1	8
321	Serum HMGB1 associates with liver disease and predicts readmission and mortality in patients with alcohol use disorder. Alcohol, 2021, 95, 37-43.	1.7	8
322	A Randomized Controlled Trial of Double Versus Triple Therapy with Amantadine for Genotype 1 Chronic Hepatitis C in Latino Patients. Digestive Diseases and Sciences, 2010, 55, 2629-2635.	2.3	7
323	Widespread Morbilliform Eruption Associated With Telaprevir. JAMA Dermatology, 2014, 150, 756.	4.1	7
324	Maternal knowledge of the risk of vertical transmission and offspring acquisition of hepatitis B. Annals of Hepatology, 2020, 19, 388-395.	1.5	7

#	Article	IF	Citations
325	Anti-hepatocellular carcinoma properties of the anti-alcoholism drug disulfiram discovered to enzymatically inhibit the AMPK-related kinase SNARK in vitro. Oncotarget, 2016, 7, 74987-74999.	1.8	7
326	Changes in serum hepatitis B surface and e antigen, interferonâ€inducible protein 10, and aminotransferase levels during combination therapy of immuneâ€tolerant chronic hepatitis B. Hepatology, 2022, 76, 775-787.	7.3	7
327	Assessment of efficacy of treatment in HCV: Infection and disease. Journal of Hepatology, 2006, 44, S56-S59.	3.7	6
328	In HIV/hepatitis C virus co-infected patients, higher 25-hydroxyvitamin D concentrations were not related to hepatitis C virus treatment responses but were associated with ritonavir use. American Journal of Clinical Nutrition, 2013, 98, 423-429.	4.7	6
329	Short and Long-Term Effects of Telaprevir on Kidney Function in Patients with Hepatitis C Virus Infection: A Retrospective Cohort Study. PLoS ONE, 2015, 10, e0124139.	2.5	6
330	Fine-mapping of genetic loci driving spontaneous clearance of hepatitis C virus infection. Scientific Reports, 2017, 7, 15843.	3.3	6
331	Balancing the risk and rewards of utilizing organs from hepatitis C viremic donors. Current Opinion in Organ Transplantation, 2019, 24, 351-357.	1.6	6
332	Apolipoprotein B100 is required for hepatitis C infectivity and Mipomersen inhibits hepatitis C. World Journal of Gastroenterology, 2016, 22, 9954.	3.3	6
333	Trans-ancestral fine-mapping of MHC reveals key amino acids associated with spontaneous clearance of hepatitis C in HLA-DQβ1. American Journal of Human Genetics, 2022, 109, 299-310.	6.2	6
334	Cytokine polymorphisms and hepatocellular carcinoma. Cancer, 2005, 103, 654-656.	4.1	5
335	HCV compartmentalization in HCC: driver, passenger or both?. Nature Reviews Gastroenterology and Hepatology, 2016, 13, 254-256.	17.8	5
336	Process of selecting and educating HCVâ€uninfected kidney waitingâ€list candidates for HCVâ€infected kidney transplantation. Artificial Organs, 2019, 43, 913-920.	1.9	5
337	Hemojuvelin Acts as a Bone Morphogenetic Protein Co-Receptor To Regulate Hepcidin Expression.. Blood, 2005, 106, 511-511.	1.4	5
338	Implementation of a controlled human infection model for evaluation of HCV vaccine candidates. Hepatology, 2023, 77, 1757-1772.	7.3	5
339	Update on hepatitis B and C coinfection in HIV. Current Infectious Disease Reports, 2005, 7, 299-308.	3.0	4
340	When Treating Cancer, Please Don't Forget Hepatitis B. Oncologist, 2010, 15, 826-829.	3.7	4
341	Host Genetic Variant in CXCL16 May Be Associated With Hepatitis B Virusâ€"Related Acute LiverÂFailure. Cellular and Molecular Gastroenterology and Hepatology, 2019, 7, 477-479.e4.	4.5	4
342	Performance of Serum-Based Scores for Identification of Mild Hepatic Steatosis in HBV Mono-infected and HBVâ€"HIV Co-infected Adults. Digestive Diseases and Sciences, 2022, 67, 676-688.	2.3	4

#	Article	IF	Citations
343	The 2020 Nobel Prize for Medicine or Physiology for the Discovery of Hepatitis C Virus: A Triumph of Curiosity and Persistence. Hepatology, 2021, 74, 2813-2823.	7.3	4
344	Just say â€œnoâ€•to viral hepatitis?. Hepatology, 1994, 19, 790-792.	7.3	3
345	Rethinking hepatitis C viral kinetics: Insights into host-virus interactions in â€˜difficult-to-treatâ€™ groups and implications for novel treatment approaches. Journal of Hepatology, 2005, 43, 748-750.	3.7	3
346	Comments on cochrane review on directâ€acting antivirals for hepatitis C. Hepatology, 2017, 66, 1016-1019.	7.3	3
347	New approaches in viraemic organ transplantation and antiviral therapies. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 78-79.	17.8	3
348	Acute Kidney Injury Following Paracentesis Among Inpatients With Cirrhosis. Kidney International Reports, 2020, 5, 1305-1308.	0.8	3
349	The risk of hepatitis C virus recurrence in hepatitis C virusâ€infected patients treated with directâ€acting antivirals after achieving a sustained virological response: A comprehensive analysis. Liver International, 2021, 41, 2341-2357.	3.9	3
350	A Prospective Cohort Study of Novel Markers of Hepatitis B Virus Replication in Human Immunodeficiency Virus Coinfection. Clinical Gastroenterology and Hepatology, 2023, 21, 125-135.e8.	4.4	3
351	HIV and HCV Coinfection: Where Are We in 2010?. Current Hepatitis Reports, 2010, 9, 155-160.	0.3	2
352	Reaping the Early Harvest of the Genomics Revolution. Gastroenterology, 2010, 138, 1653-1654.	1.3	2
353	Future Classes of Hepatitis C Virus Therapeutic Agents. Infectious Disease Clinics of North America, 2012, 26, 949-966.	5.1	2
354	Impact of <scp>EGF</scp>,<scp>IL</scp>28B, and <scp>PNPLA</scp>3 polymorphisms on the outcome of allograft hepatitis C: a multicenter study. Clinical Transplantation, 2016, 30, 452-460.	1.6	2
355	Reply to antiviral therapy and hepatocellular carcinogenesis. Cancer, 2016, 122, 158-158.	4.1	2
356	Reactivation of a Vaccine Escape Hepatitis B Virus Mutant in a Cambodian Patient During Anti-Hepatitis C Virus Therapy. Frontiers in Medicine, 2018, 5, 97.	2.6	2
357	Computed Tomography Findings as a Novel Predictor of Alcohol-Associated Hepatitis Outcomes. Digestive Diseases and Sciences, 2020, 65, 312-321.	2.3	2
358	Shortening treatment with direct-acting antivirals in HCV-positive organ transplantation. The Lancet Gastroenterology and Hepatology, 2020, 5, 626-627.	8.1	2
359	Low Complement C4 Predicts Improvement of Kidney Function After Directâ€Acting Antiviral Therapy for Hepatitis C Virus. Hepatology Communications, 2020, 4, 1206-1217.	4.3	2
360	A New Model to Assess Hepatitis B Virus Covalently Closed Circular DNA: A Window Into a Previously Hidden Space?. Cellular and Molecular Gastroenterology and Hepatology, 2022, 13, 1255-1256.	4.5	2

#	Article	IF	Citations
361	Peginterferon Î±-2a improved the hepatitis C virologic response in concurrent HIV and chronic hepatitis C virus infections. ACP Journal Club, 2005, 142, A12.	0.1	2
362	A prospective cohort study of renal function and bone turnover in adults with hepatitis B virus (<scp>HBV)â€HIV</scp> coâ€infection with high prevalence of tenofovirâ€based antiretroviral therapy use. HIV Medicine, 2023, 24, 55-74.	2.2	2
363	HIV and hepatitis C virus coinfection update. Current Hepatitis Reports, 2004, 3, 83-90.	0.3	1
364	The Role of Early Viral Decline in the Treatment of Hepatitis C in HIV-1-Coinfected Persons. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 46, 371-373.	2.1	1
365	Reply to: â€œCoagulation and fibrosis: A potential non-negligible target of statins in chronic hepatitisâ€• Journal of Hepatology, 2015, 63, 279.	3.7	1
366	The Polymerase Chain Reaction: Essential for the Development of Curative Therapy for Hepatitis C. Digestive Diseases and Sciences, 2015, 60, 2232-2235.	2.3	1
367	The Incidence of Hepatocellular Carcinoma Is not Increased in Individuals with Chronic Hepatitis C After Treatment with Interferon-free Regimens: an ERCHIVES Study. Open Forum Infectious Diseases, 2017, 4, S41-S41.	0.9	1
368	Reply. Hepatology, 2018, 67, 1641-1642.	7.3	1
369	An exploratory analysis of the competing effects of alcohol use and advanced hepatic fibrosis on serum HDL. Clinical and Experimental Medicine, 2021, , 1.	3.6	1
370	Mutations in the NS5A region do not predict interferonâ€responsiveness in American patients infected with genotype 1b hepatitis C virus. Journal of Medical Virology, 1999, 58, 353-358.	5.0	1
371	Cognitive Tests and Stool Frequency at Hospital Discharge Do Not Predict Outcomes in Hepatic Encephalopathy. Southern Medical Journal, 2020, 113, 578-584.	0.7	1
372	Reply. Hepatology, 2022, 75, 1055-1056.	7.3	1
373	LOXL-2 and TNC-C are markers of liver fibrogenesis in HCV/HIV-, HIV- and HCV-infected patients. Biomarkers in Medicine, 0, , .	1.4	1
374	New antiviral therapies for hepatitis C. Expert Review of Anti-Infective Therapy, 2004, 2, 235-243.	4.4	0
375	Development of novel agents for the treatment of hepatitis C virus. Hepatology, 2008, 47, 1426-1426.	7.3	0
376	Reply:. Hepatology, 2008, 47, 2142-2143.	7.3	0
377	Reply:. Hepatology, 2010, 51, 343-344.	7.3	0
378	Reply. Gastroenterology, 2013, 144, e26.	1.3	0

#	Article	IF	Citations
379	Reply to directâ€acting antiviral drugs and hepatitis C virus: A therapeutic revolution?. Cancer, 2015, 121, 4269-4270.	4.1	0
380	Direct-Acting Antiviral (DAA) Therapy for Chronic Hepatitis C Virus (HCV) Infection Leads to Regression of Liver Fibrosis, Assessed by Serial Transient Elastography (Fibroscan). Open Forum Infectious Diseases, 2016, 3, .	0.9	0
381	Lipid Levels and the Risk of Acute Myocardial Infarction Among Hepatitis C Virus (HCV) Infected and Uninfected Persons: Results From ERCHIVES. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
382	Reply. Hepatology, 2016, 63, 2066-2067.	7.3	0
383	Reply. Hepatology, 2017, 66, 1005-1006.	7.3	0
384	Reply. Clinical Gastroenterology and Hepatology, 2017, 15, 1981.	4.4	0
385	Reply. Hepatology, 2018, 68, 793-793.	7.3	0
386	Editorial: mind the gaps â€•an important first step towards improving hepatic encephalopathy care. Alimentary Pharmacology and Therapeutics, 2019, 49, 1534-1535.	3.7	0
387	Reply. Hepatology, 2021, 73, 875-876.	7.3	0
388	OUP accepted manuscript. Clinical Infectious Diseases, 2021, , .	5.8	0
389	Growth Hormone Releasing Hormone Reduces Plasma Markers of Immune Activation and Hepatic Immune Pathways in Nonalcoholic Fatty Liver Disease. Journal of the Endocrine Society, 2021, 5, A628-A629.	0.2	0
390	Hepatitis C Virus Treatment in HIV. , 2012, , 133-139.		0
391	Reply. Hepatology, 2022, 75, 761-763.	7.3	0
392	Preliminary evaluation of [11C]MAGL-0519 as a promising PET ligand for the diagnosis of Hepatocellular carcinoma. Bioorganic Chemistry, 2022, 120, 105620.	4.1	0
393	New developments in the management of hepatitis B virus/HIV coinfection. MedGenMed: Medscape General Medicine, 2002, 4, 20.	0.2	0
394	Substance Use Disorder Is Associated With Alcohol-Associated Liver Disease in Patients With Alcohol Use Disorder. , 2022, 1, 403-408.		0
395	Reply to Li, Henry, and Nguyen. American Journal of Gastroenterology, 2022, 117, 688-688.	0.4	0
396	Abstract 255: Peroxidasin deficiency recruits pro-healing macrophages into the liver and inhibits NAFLD progression to HCC. Cancer Research, 2022, 82, 255-255.	0.9	0